Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -28.79% | -9.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.95% | -9.74% | |||
| Operating Income | -8.95% | 9.74% | |||
| Income Before Tax | 122.30% | -21.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 122.30% | -21.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 122.30% | -21.46% | |||
| EBIT | -8.95% | 9.74% | |||
| EBITDA | -8.90% | 9.70% | |||
| EPS Basic | 122.32% | -19.65% | |||
| Normalized Basic EPS | 122.22% | -19.76% | |||
| EPS Diluted | 122.32% | -19.65% | |||
| Normalized Diluted EPS | 122.22% | -19.76% | |||
| Average Basic Shares Outstanding | 0.23% | 1.52% | |||
| Average Diluted Shares Outstanding | 0.23% | 1.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||